• The USDA is set to include hemp data in its 2022 Census of Agriculture, another indication of the ongoing growth in support of the overall cannabis industry, benefitting related mortgage origination and financing company REZYFi, Inc.
• The legal marijuana industry is set to hit 53% in 2026, a 60% growth, with international legal marijuana sales expected to hit $130 billion by 2030
• REZYFi is confident that this move by the USDA will yield further growth in the cannabis sector, supporting demand for its product offerings as it expands to additional states throughout the U.S.

In 2014, the Farm Bill, regarded as a monumental step towards the legalization of hemp and marijuana, opened the door for the Hemp Research Pilot Program. The program would allow for hemp cultivation for research purposes, kickstarting a budding multi-billion-dollar industry. The 2018 Farm Bill expanded on the provisions offered by the 2014 Farm Bill, further establishing the Domestic Hemp Production Program and even pushing for the amendment of the Agricultural Marketing Act. This program was administered by the United States Department of Agriculture (“USDA”) (https://ibn.fm/cU5sB). In what marks another notable move in the right direction, the USDA is set to include hemp data in its 2022 Census of Agriculture. It is noted that with this inclusion, the organization is pushing the conversation around hemp and marijuana forward. It also signals the eventual integration and support of the overall cannabis industry (https://ibn.fm/5nwGL). With this support, various companies within the sector are set to benefit, REZYFi being one of them. REZYFi is a growth mortgage origination and specialized financing company based in the United States. It originates, structures, and invests in first mortgage loans and alternative structured financings, targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related and additional mortgage-based financing. It is estimated that by 2026, the legal marijuana industry will have grown by 60% to hit $53 billion, with total international legal marijuana sales expected to hit $130 billion by 2030 (https://ibn.fm/Zpb2F). This growth will have a positive financial upside, down to a state level, as evidenced by Arizona’s $284 million tax revenue collection since it legalized marijuana. Additional upsides will include increased investment opportunities, job growth, and savings (https://ibn.fm/8g9Rf). REZYFi is banking on the federal legalization of this product. Its management is optimistic that this recent move by the USDA to include hemp data is a step in the right direction. More importantly, the company understands that this inclusion gives farmers a voice in the matter and the power to influence policy in a way that would favor the industry’s growth. “The 2022 Census of Agriculture is a powerful voice for American Agriculture,” noted Tom Vilsack, the Agriculture Secretary. “The information gathered through the ag census influences policy decisions that will have a tremendous impact on ag producers and their communities for years to come. This is your opportunity to share your voice, uplift the value and showcase the uniqueness of American agriculture,” he added. Freddie Mac, a home loan mortgage corporation, projected a 10.4% increase in home prices in 2022 and a 5% bump in 2023 (https://ibn.fm/sOvEl). REZYFi notes that the cannabis industry is expected to paint a similar picture, which would be integral to its growth. The increasing support of the cannabis industry is proving more promising while presenting many growth opportunities for companies such as REZYFi. As such, the company is confident that it will continue experiencing growth as the demand for its offerings continues to grow and as it also expands to various states within the country. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers
• CNS’s flagship drug candidate is called Berubicin, a product initially developed by another company with encouraging small-population results in 2006, and CNS is expanding the testing with expectations of eventually delivering an innovative new GBM treatment to market
• The company aims to enroll more than 200 patients in its global Berubicin trial on a 2:1 randomization schema comparing Berubicin-treated patients to those receiving second-line standard of care chemotherapy agent lomustine
• The company recently reported that patient enrollment has risen to 67 across its varied sites, with plans to provide an interim analysis of the trials’ progress in mid-2023

A Phase 2, globally sited clinical trial evaluating the potential efficacy of a promising brain cancer drug candidate against deadly glioblastoma (“GBM”) tumors is proceeding apace with a variety of patient profiles, affirming the drug developer’s confidence in its product. 

In a Dec. 8 news release, CNS Pharmaceuticals (NASDAQ: CNSP) reported that 67 patients have enrolled in the potentially pivotal study comparing drug candidate Berubicin’s effectiveness to second-line standard of care chemotherapy drug lomustine.

GBM tumors are aggressive, with most patients dying within about a year of diagnosis and only 10 percent or less surviving to five years. First-line treatment generally involves surgical removal of as much of the tumor as possible, followed by targeted radiation therapy. But because of the difficulty in removing the entire tumor from critical function brain cells, the cancer usually regrows, making it practically 100 percent fatal.

Second-line chemotherapy treatment tends to have limited effectiveness, in large part because scientists have been unable to demonstrate that anthracyclines used in chemotherapy can cross the blood-brain barrier and achieve significant levels of activity in the brain. But Berubicin has demonstrated a unique ability to cross the blood-brain barrier.

“Although data are still early, we are pleased with these results in terms of recruiting a balanced patient population to compare Berubicin to Lomustine in the treatment of GBM, which may highlight Berubicin’s potential to provide a better therapeutic option for patients after first-line therapy for their disease,” CNS Pharmaceuticals CEO John Climaco stated in the news release (https://ibn.fm/ZbgT2). “We remain steadfast in our efforts to drive patient enrollment across the U.S. and Europe and are making significant progress toward our planned interim analysis, which we expect to occur in mid-2023.”

The company’s recent report notes that between the Berubicin and lomustine arms of the ongoing trial, demographics including age, gender and race are comparable and that the percentage of patients continuing on study or having withdrawn is also comparable.

The company plans to have more than 200 patients participate in the clinical trial on a 2:1 randomization schema between those receiving Berubicin and those receiving lomustine. Prior stages of the clinical study have examined Berubicin’s safety in human patients and potential effectiveness against lab cells.

Berubicin’s performance in an initial safety trial conducted by another company in 2006 resulted in apparent life extension for some patients and complete remission for one patient who, unusually, survives nearly 17 years later.

The ongoing study now seeks to demonstrate overall survivability of GBM patients using Berubicin, established by a decrease in the size of the tumor, arrested development of the tumor’s size once the patient is put on study, and / or a favorable change in the time to progression of the tumors.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Cannabis cultivator and international brand developer Flora Growth has continued to build its revenues through accretive acquisitions during the past year and expects to see revenues continue to rise amid further M&A activity
• Flora expects to lock in its latest acquisition by the end of the month after shareholders meet to discuss the proposed deal with multi-national operator Franchise Global Health (“FGH”), which would grant Flora immediate access to Germany’s cannabis market and FGH the ability to overcome supply chain difficulties
• Flora has previously reported cooperative agreements that increase its product distribution pipeline in Europe through Switzerland and the Czech Republic

In spite of outside pressures on the cannabis sector, some analysts are predicting a reversal in the trend during the coming months (https://ibn.fm/NDYRj), and the most resourceful companies are continuing to build income channels amid the slowdown.

International cannabis cultivator, Flora Growth (NASDAQ: FLGC) has boosted its YOY revenues more than five fold since Q3 2021 thanks to its strategic acquisitions, and its ambitious growth outlook includes the establishment of a global presence in key markets while creating an ecosystem for its multiple cannabis and wellness brands.

Flora Growth’s newest effort to boost its portfolio comes in the form of an agreement to acquire multi-national operator Franchise Global Health Inc., a company that serves 1,200 pharmacies in Germany through its wholly owned subsidiaries ACA Muller and Phatebo.

Flora Growth believes the acquisition will be transformative, enabling it to connect its Colombian-grown cannabis directly with German-based pharmaceutical and medical cannabis distribution. Franchise Global Health will hold a special shareholder meeting to review the pending acquisition this month, and Flora expects the deal to close by year’s end, according to a company news release (https://ibn.fm/RqHit). [See https://ibn.fm/rIBPK for full Zacks Small-Cap Research report.]

Flora has already been making inroads into Europe thanks to a new openness to creating a framework for legal cannabis exports by Colombia’s administration.

“We are proud to help increase access to safe, legal CBD and THC to consumers all over the globe,” Flora Growth Chairman and CEO Luis Merchan stated in September following the company’s first exports of high-CBD dried cannabis flower to Switzerland and the Czech Republic (https://ibn.fm/Zx9O0).

Franchise Global Health has also paired operations with strategic partnerships and investments in St. Vincent and the Grenadines, Portugal and Denmark, indicating further possibilities for expanding Flora’s distribution network.

The company’s efforts caught the eye of market analysts at year’s end, who significantly upgraded their near-term revenue forecasts while also reducing their loss estimates as the company drives toward profitability (https://ibn.fm/bRP8l).

FGH CEO Clifford Starke has said he regards the merger with Flora to be the foundation of “a very sustainable business.”

“We have extremely strong revenue performance without executing on really what we’re trying to do, which is become a fully integrated medical cannabis company of high THC products,” Starke said during a webcast interview in October (https://ibn.fm/3cz8e). “We’re extremely well positioned to go past Germany into the rest of Europe. It’s very important to understand that 75 to 80 percent of the sales in Europe are accounted in Germany.”

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Studies have indicated that around 40% of the available drugs on the market offer poor bioavailability
• Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
• The global pharmaceutical drug delivery market was valued at $1.66 billion in 2021 and is expected to grow at a CAGR of 5.9%, resulting in a value of $2.21 billion by 2026

One of the main concerns associated with marketed drugs is low bioavailability. Bioavailability is the amount of a drug or substance that becomes completely available to the intended biological destination and is a measure of the rate and fraction of the initial dose of the drug that successfully reaches either the site of action or the bodily fluid domain in which the intended target has unimpeded access. Bioavailability is integral to pharmacokinetics, the study of drug movement through the body. Pharmacokinetics is often represented by the acronym ABCD – administration, bioavailability, clearance, and distribution (https://ibn.fm/7lOOa). Various studies have indicated that around 40% of available drugs are poorly bioavailable (soluble) (https://ibn.fm/bY8Vx). Many factors can affect the bioavailability of drugs and substances, including:

• The size of the drug’s molecule – smaller molecules are more easily absorbed into the body than larger ones
• The type of drug administered – some drugs are absorbed more easily through the stomach than others
• How much food is eaten – food can slow down the absorption process
• The time of day – the absorption of drugs can be affected by factors like the time of day or the mood of the recipient

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a patented technology, DehydraTECH(TM), which improves the bioavailability of active pharmaceutical ingredients (“APIs”), promotes healthier oral ingestion methods and increases the effectiveness of fat-soluble active molecules. DehydraTECH technology is suitable for use with various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Currently, DehydraTECH-CBD is being studied for the potential treatment of hypertension and heart disease, epilepsy, dementia and diabetes. Lexaria’s DehydraTECH solves common problems experienced in the pharmaceutical industry. DehydraTECH technology can increase bioabsorption by up to 10x, reduce the onset time from up to 1-2 hours to just minutes, mask the unwanted taste, delivers drugs into the bloodstream more effectively, and provides a higher ratio of drug delivery expected to lower overall drug costs. The global pharmaceutical drug delivery market size is projected to reach $2.21 billion by 2026, growing at a CAGR of 5.9%. The market was valued at $1.66 billion in 2021. This growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements – including new product launches (https://ibn.fm/hgQhh). Understanding the bioavailability of a drug is crucial for clinicians looking for the most appropriate route of administration and schedule for delivering the drug. Lexaria is currently studying its DehydraTECH and DehydraTECH-CBD for indications including epilepsy, high blood pressure, dementia, diabetes and more. The company’s most recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. These findings further support Lexaria’s efforts and clinical trials, which are currently being explored for hypertension, dementia, diabetes and other indications where DehydraTECH technology may offer solutions in indications where there is an underserved medical need. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Hillcrest is poised to accelerate its efforts to expand into grid-tied applications to help diversify future revenue streams; continues development of its Enhanced Powertrain Solution to bridge the gap between EVs and universal, bidirectional charging systems
• Its unique application-agnostic ZVS inverter technology allows the company to quickly adapt its technology to any motor or grid application, setting it up for entry into renewable energy generation and storage, as well as e-mobility charging
• Hillcrest’s Enhanced Powertrain Solution is expected to simplify the overall EV powertrain and charging system and free EVs from the need for an onboard charger or additional onboard DC/DC booster unit

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) has announced that the Company is accelerating its developmental efforts focused on grid-tied power conversion technologies as it completes the first Zero Voltage Switching (“ZVS”) inverter commercial prototype (https://ibn.fm/2FiVp). This clean technology developer of transformative power conversion technologies and control system solutions for modern electrical systems, expects the completion and commercialization of its grid-tied products will constitute the bedrock for the Company’s penetration into green energy applications, thus contributing to the diversification of its future revenue streams. “Our ZVS inverter technology is intentionally designed to be decoupled from the power control system, making our firmware agnostic to specific applications, allowing us to move quickly to adapt our technology to any motor or grid application,” said Chief Technology Officer Ari Berger. “With the completion of our 800-volt, 250-kilowatt traction inverter commercial prototype, we’ve set the foundation to facilitate our entry into grid-tied applications such as renewable energy generation and storage, as well as e-mobility charging,” continued as he unveiled the Company’s plans for the future. Progressing from technical proof of concept to commercial prototype in only one year, Hillcrest’s ZVS is designed to offer benefits not currently available in most electric power systems, including perks such as a more efficient and reliable deployment of higher switching frequencies and enhanced output power quality and control. This novel technology can be applied with batteries, electric motors, generators, fuel cells, or essentially any other power source where power conversion is needed, including grid, solar and wind. The Company takes a building block approach to the development, meaning it will start with EV applications and then look to expand into other areas of the rapidly growing clean technology sector that is booming worldwide (https://ibn.fm/2Bz8S). 2022 marks the year when the United States became the 19th country in the world, where 5% of new car sales were electric vehicles – a threshold believed to be a tipping point toward mass adoption (https://ibn.fm/NbWrs). In addition, the 2022 US Inflation Reduction Act is expected to give the cleantech sector another strong boost as it unlocks $370 billion in climate and energy investment across the country (https://ibn.fm/CCBgS). The new breed of grid-tied energy systems will require high-frequency power electronics to allow the smart, grid-forming capabilities of a more distributed, bidirectional system that includes a variety of intermittent sources. The Company’s development of firmware and hardware that allows its ZVS inverter technology to be deployed into grid-tied applications, including renewable energy generation, storage and EV charging infrastructure, could pave the road toward acceleration of the development of its Enhanced Powertrain Solution (“EPS”) — a universal, bidirectional V2X charging architecture that leverages the efficiency and high switching frequency capabilities of Hillcrest’s ZVS inverter technology. With its unique ZVS inverter technology, EPS simplifies the overall powertrain and charging system and is designed to free EVs from the need for an onboard charger or additional onboard DC/DC booster unit. Since onboard chargers are responsible for charging losses of up to 14%, their elimination from the system could instantly lead to charging efficiency gains, offering advantages such as reduced charging times and costs. Also, booster units are usually of a similar size and cost to the EVs traction inverter, so their removal could streamline EVs and substantially reduce weight and cost. As the momentum for an electrified future shows no sign of slowing down, Hillcrest Energy aims to deliver advanced inverter and EV powertrain technology that has the potential to transform power electronics for the new generation of mobility, ultimately redefining how we manage energy on the grid, charge vehicles and redeploy stored energy to stabilize systems. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls
• MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up listing on a national exchange
• The company’s products include its flagship patented shoe insole device enabled with GPS, Bluetooth, and Wi-Fi functionality for tracking seniors or people with autism prone to wandering and getting lost, as well as protecting potential kidnapping targets
• MetAlert’s latest product developments provide artificial intelligence as an accessory to identify fall risks and provide related analysis of patients’ physical functioning, while allowing the patient to maintain a degree of privacy and independence

Medical patient location device developer MetAlert (OTC: MLRT) is launching a suite of wearable companion products to its innovative SmartSole shoe insole units and, on the heels of rebranding the company to better represent its strategic direction, recently announced that it has engaged financial advisory firm Joseph Gunnar & Co., LLC to guide its financing and acquisition decisions.

“MetAlert is approaching the inflection point of its growth curve by its ability to sell a multitude of products and services to a broader audience, which will result in greater revenue per user (“RPU”),” MetAlert CEO Patrick Bertagna stated (https://ibn.fm/0eYGw). “We are thrilled to align with a proven advisor like Joseph Gunnar in our quest to maximize shareholder value.”

The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The tech-designed insole may also be used by people at risk of kidnapping, such as children, government employees and select professionals.

A next-generation shoe insole branded SmartSole plus incorporates biometric sensors paired with smart analytics to analyze the wearer’s movements for assessing overall health and wellness, and the company’s most recent product rollout — the in-home RoomMate system — uses 3D infrared motion-sensitive technology to allow caregivers to remotely monitor fall-prone loved ones in an unobtrusive manner.

Such developments have given the location technology pioneer a new progressive profile designed to encourage investors and strengthen the company’s profitability (https://ibn.fm/eTt7E).

The market potential for location and fall-monitoring devices is demonstrated by Centers for Disease Control and Prevention reporting that notes U.S. emergency departments treat 3 million older adults each year for fall injuries and more than 650,000 people are believed to have died each year as a result of accidental falls (https://ibn.fm/IGNcY).

MetAlert’s international distribution supply chain serves customers in over 40 countries as well as U.S. clients ranging from police departments to assisted living facilities.

Developments anticipated during the first months of 2023 include the rollout of Bluetooth-enabled devices that will collect patients’ health data such as their vitals and, in connection with the GPS SmartSole plus HUB and artificial intelligence software, will analyze trends and provide responsiveness according to preset alert parameters.

A small GPS tracker shorter than the length of a credit card will provide the same functionality as the insoles and have a two-week battery life between charging.

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• Correlate addresses anticipated questions about energy retrofits for the commercial and industrial sector through its industry-leading advanced energy solution and financing platform
• The company is reducing the overall barrier of entry into the renewable energy space while also aiding in the installation and overall maintenance of high-efficiency infrastructure
• The company has developed a network of financing partners to cater to project needs, allowing even more customers to access renewable energy solutions for their buildings to reduce their overall carbon footprint, while helping to ensure positive economic return of retrofits in a much shorter timeframe

According to the National Renewable Energy Laboratory, buildings are the largest consumers of energy and one of the largest sources of greenhouse gas (“GHG”) emissions in the United States. They account for 70% of electricity use and about 40% of total primary energy consumption in the country. In 2020, carbon dioxide (“CO2”) from energy use in buildings accounted for about 37% of global emissions (https://ibn.fm/9TgmT). To remedy the situation, electrification retrofits that remove fossil gas are being seen as a critical climate solution, given their overall efficiency and sustainability. Legitimate concerns that building owners have regarding short and long-term returns of potential retrofits are addressed by Correlate Infrastructure Partners (OTCQB: CIPI), a distributed energy solutions company, through its advanced energy solution and financing platform. Correlate, providing efficient and affordable energy solutions across North America, sees the scaling of distributed clean energy solutions as critical and doable in countering the effects of climate change. Through its two subsidiaries, Correlate and Solar Site Design, the company sees a unique market opportunity to reduce site-specific energy consumption and deploy clean energy generation and clean energy solutions at scale, focusing on retrofitting commercial buildings. Through its unique commercial and industrial sector platform, Correlate meets the economic concerns of building owners in retrofitting their establishments. The company is reducing the overall barrier of entry into the renewable energy space with its finance model while also aiding in the installation and overall maintenance of the installed infrastructure, ultimately making it easier for customers to transition to renewable energy alternatives. Since its inception, Correlate has sought to remove friction between today’s legacy finance processes and the needed clean-energy upgrades developed within its program technologies. To this end, it has developed a network of financing partners to cater to most project financing needs. This allows even more customers access to renewable energy solutions for their buildings and proper energy management and improvement projects specifically tailored to reduce the overall buildings’ carbon footprint. As the cost of solar components continues to drop, Correlate is confident that more building owners will embrace solar power as an alternative energy source to lower their carbon footprint. The company’s management is also confident that through its finance platform and the network built so far, Correlate will continue to offer value to its customers, guaranteeing the economic return of their retrofits in a much shorter timeframe. “Correlate Infrastructure Partners is making energy management and procurement transparent and cost-effective as we digitize the process that has been archaic for way too long,” noted Todd Michaels, Correlate’s CEO. “We are excited to be at the forefront of an industry that is at an inflection point, and we are eager to begin working to change the way commercial real estate owners optimize energy assets,” he added (https://ibn.fm/qnu3Q). For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.correlateinfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.correlateinfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Meta was recently fined $275 million by the Irish Data Protection Commission stemming from a hack in 2019, which led to the leak of over 533 million users’ personal data
• By 2023, over 65% of the world’s population is set to be subject to data protection laws, up from only 10% in 2020
• This number is set to gain further impetus with the recent passing of the U.S. ADPPA law, which will afford U.S. internet users similar rights to those granted under the European Union’s GDPR laws
• Reklaim Ltd. has looked to assist companies in incorporating the demands of a rapidly evolving privacy landscape into their data strategies

In the weeks leading up to August 2019, matters were tense at Meta (previously Facebook). A security hack had exposed personal information on over 533 million Facebook users spread across 106 countries. The social media company subsequently revealed that it had discovered and fixed the issue in August 2019, expressing confidence that the same route could no longer be used to scrape data. Less than 24 months later, phone numbers, full names, locations, and email addresses drawn from the hacked user profiles were posted to an amateur hacking forum (https://ibn.fm/vOKpp). The matter has now come to a head, with Ireland’s Data Protection Commission fining Facebook parent Meta roughly $275 million – taking the cumulative fines the regulator imposed on Meta since last year to over $900 million. With data privacy regulations turning increasingly stringent, companies and users alike have placed greater emphasis on safeguarding their online data – a phenomenon that Reklaim (TSX.V: MYID) (OTCQB: MYIDF) has sought to address. By 2023, 65% of the world’s population is set to have its personal data covered under modern privacy regulations, up from a mere 10% in 2020 (https://ibn.fm/Gbm5K). “With more countries introducing modern privacy laws in the same vein as the General Data Protection Regulation (‘GDPR’), the world has reached a threshold where the European baseline for handling personal information is now the de facto global standard,” Nader Henein, research vice president at Gartner, said in a news release. The strong momentum underpinning the expansion of global data privacy laws has made it imperative for businesses to incorporate the demands of a rapidly evolving privacy landscape into their data strategies. A failure from a business’s security and risk management department to adapt their personal data handling practices could increasingly expose the company to loss through fines or reputational damages, as highlighted by Meta’s recent travails. The ongoing evolution of consumer data and privacy rules has largely influenced Reklaim Ltd.’s business model. The company’s revolutionary systems allow consumers to log in to its platform and confirm their identity, unlocking data collected on them that has been bought and sold for years without their explicit consent. At that point, consumers can take control of their data and, if they choose, receive compensation for its use. With consent secured, Reklaim offers the data to Fortune 500 brands, platforms, and data firms. The company also has a subscription service for consumers that shrinks the amount of data leaking from their devices and delivers alerts on password and third-party data breaches (https://ibn.fm/0O5Hs). Reklaim’s data provision services have gained additional relevance amidst a spate of new consumer privacy regulations coming into effect. The recently passed federal American Data Privacy and Protection Act (“ADPPA”), a new privacy law promising Americans many of the same consumer privacy rights as the European Union’s General Data Protection Regulation (“GDPR”), will make the protection of online consumer data privacy a nationwide requirement. Meanwhile, on a state level, the California Consumer Privacy Act (“CCPA”) will become fully operational as of January 1, 2023, with the regulations affording consumers the right to know about the personal information a business collects about them as well as how it is used and shared (https://ibn.fm/L64ru). With the data privacy market in the U.S. and globally set to grow at a breakneck pace in the coming years, Reklaim Ltd. looks well positioned to capitalize. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• CNS Pharmaceuticals is a biopharmaceutical company that focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous system
• The company is currently evaluating the efficacy of Berubicin, a novel anthracycline that appears to cross the blood-brain barrier, in a potentially pivotal Phase 2 trial involving patients with recurrent glioblastoma multiforme (“GBM”)
• CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event in which he provided an update on recent key events and plans for the future in addition to allaying the investors’ concerns regarding the recent reverse stock split
• CNS Pharmaceuticals also announced the pricing of a public offering that closed December 5; the company intends to use the net proceeds of the offering for its ongoing trial, R&D, and working capital

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event held December 6. As part of the virtual event, Climaco discussed his and the company’s background, provided an update on recent key events and plans for the 2023 calendar year, and assuaged investors’ concerns regarding the recent reverse stock split. Lastly, Climaco also fielded questions from the investment community (https://ibn.fm/bEl2S). A clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, CNS Pharmaceuticals is presently enrolling patients in a potentially pivotal Phase 2 trial to evaluate the efficacy of Berubicin, its flagship drug candidate for the treatment of glioblastoma multiforme (“GBM”) and potentially other forms of cancer. So far, according to Climaco, the enrollment is approaching 70 patients against a target of 243 patients, a remarkable achievement since it began about 14 months earlier. “Patients are a lifeblood of a trial like this,” Climaco explained. “Our target is recurring and refractory GBM patients, and sadly in this deadly cancer, almost everyone will recur. And when they do, they do not have any approved treatment option anywhere in the world…. We’ve now offered those patients a chance at a chemotherapy that we believe can have efficacy and change the outcome of this disease.” GBM is an aggressive brain tumor with an average overall survival rate of only 10-12 months. “Most patients experience recurrence or progression of their disease within 12 months after frontline therapy and face a dismal outcome with no effective therapy,” a 2019 study explains (https://ibn.fm/q6snr). This lack of effective therapy is partly because conventional anthracyclines cannot cross the blood-brain barrier. But Berubicin changes this narrative as it is the first anthracycline with the demonstrated ability to cross this barrier and kill brain tumor cells otherwise unreachable by other therapies. “In other words,” the company’s website underlines, “Berubicin may become an effective treatment against glioblastoma, the most aggressive type of brain cancer.” To prove this hypothesis and demonstrate the drug candidate’s efficacy, CNS Pharmaceuticals set out to undertake an elaborate potentially pivotal Phase 2 trial designed in close collaboration with the US Food and Drug Administration (“FDA”). The trial aims to establish whether Berubicin extends overall survival, the primary endpoint of the trial and, as Climaco explained, “the only endpoint the FDA recognizes as the approvable endpoint.” The trial’s design encompasses a built-in interim analysis that will commence when the company enrolls 30-50% of the targeted figure and will last for six months. “When that [six-month period elapses], we will examine that data, and we will look to see if those patients are living longer than they are in the control arm. And if they are, and we believe they will, the study will continue. Our firmest hope is the data will be so conclusive that we may have the opportunity to discuss an accelerated approval with the FDA,” Climaco continued. CNS Pharmaceuticals expects to release the data from this interim analysis, potentially in mid-2023. The company believes that Berubicin, an anthracycline, has a real shot at changing the game in GBM in a way no one else has been able to do before. At the same time, the company believes Berubicin could be used to treat multiple other cancers, with Climaco describing the drug candidate as a “sledgehammer in oncologists’ toolkit.” Moreover, Climaco explained the reasons behind the company’s move to undertake a 1-for-30 reverse split of its common stock, which was announced November 28 (https://ibn.fm/wTksP). The split freed up shares, allowing the company to announce a $6 million public offering that closed December 5 (https://ibn.fm/2Ikp9). As part of this latest capital raise, CNS announced the pricing of a public offering of an aggregate of 1,889,764 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,889,764 shares of common stock at a combined offering price of $3.175 per share. The warrants were immediately exercisable at an exercise price of $3.03 per share and will expire five years after the initial exercise date. In addition, CNS also announced amendments to certain existing warrants. CNS Pharmaceuticals intends to use the net proceeds of the offering for its Phase 2 clinical trial, other research and development initiatives, and working capital. Following this most recent capital raise, the company is fully funded until late Q3 into early Q4 2023. A recording of the Virtual Investor “Ask the CEO” Event is available for 90 days post-event via https://ibn.fm/7aFjv. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• REZYFi is targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners who seek a variety of real estate-related first and additional mortgage-based financing and project-specific financing
• The sale of legal recreational marijuana in California in 2016 reached $2.69 billion and is expected to grow to $6.59 billion by 2025. Since passing laws for recreational marijuana, California saw a 50% increase in the legal marijuana market from 2017 to 2018
• REZYFi is licensed in 36 states and plans to expand to all states in the future

Throughout most of 2022, mortgage rates were rising due to the Federal Reserve’s increased interest rates to counter soaring inflation. However, mortgage rates have started dropping in recent weeks, reporting a downward trend for the fifth consecutive week. According to Freddie Mac, the 30-year fixed-rate mortgage averaged 6.31% in the week ending December 15, down from 6.33% during the week prior. According to the Mortgage Bankers Association, there has been an uptick in mortgage applications, with more people looking to take advantage of the trend in lower rates (https://ibn.fm/CXJOi). REZYFi is a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businesses. The company’s target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners who seek a variety of real estate-related first and additional mortgage-based financing and project-specific financing, like solar installations or real estate development projects. REZYFi has positioned itself as one of the first cannabis mortgage bankers in the United States – an area that traditional bankers are still reticent to serve. Through its two wholly owned subsidiaries – REZYFi Lending and ResMac Inc. – REZYFi is addressing an emerging real estate market with its financing opportunities, traditional mortgage, origination, correspondent, and servicing operations. The company leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. REZYFi expects increased funding for marketing and loan agents, which will drive significant origination growth over the next two years, supported by the planned launch of a high-margin cannabis division later this year. ResMac has been in operation for 13 years and has closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023. In 2016, the sale of legal recreational marijuana in California – the world’s largest cannabis market – was valued at $2.69 billion and is expected to grow to $6.59 billion by 2025. Since passing laws for recreational marijuana in 2016, California saw a 50% increase in the legal marijuana market from 2017 to 2018 (https://ibn.fm/H74Qg). Using its corporate strengths – experience, a network of independent brokers, and proprietary technology – REZYFi offers a diversified approach to the real estate lending sector, which positions it to capitalize on growth in multiple verticals in the years to come. Licensed in 36 states, the company plans to expand to all states in the future. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY